NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.
Mamounas
Eleftherios P
EP
Cancer Center, Aultman Health Foundation, Canton, OH 44710, USA.
Lembersky
Barry
B
Jeong
Jong-Hyeon
JH
Cronin
Walter
W
Harkins
Barbara
B
Geyer
Charles
C
Wickerham
Donald Lawrence
DL
Paik
Soonmyung
S
Costantino
Joseph
J
Wolmark
Norman
N
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000077289:Letrozole; D009367:Neoplasm Staging; D009570:Nitriles / Q000627:therapeutic use*; D018579:Patient Selection; D017698:Postmenopause; D013629:Tamoxifen / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077289:Letrozole